Weill Cornell researchers have found a way to wake up exhausted T cells and boost cancer-fighting power, according to the Cornell Chronicle.
The study revealed tumors hijack a protein called CD47 on T cells, using it—alongside a partner molecule, thrombospondin-1—to switch off the immune response. Blocking this interaction in mice revived T cell activity and slowed tumor growth.
A peptide called TAX2 disrupted the CD47 signal and worked even better when combined with existing immunotherapy, paving the way for stronger, longer-lasting cancer treatments.
Get the latest headlines delivered to your inbox each morning. Sign up for our Morning Edition to start your day. FL1 on the Go! Download the free FingerLakes1.com App for iOS (iPhone, iPad).
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].
